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A B S T R A C T
The advent of liquid chromatography mass spectrometry has seen a dramatic increase in the amount of
data derived from proteomic biomarker discovery. These experiments have seemingly identiﬁed many
potential candidate biomarkers. Frustratingly, very few of these candidates have been evaluated and
validated sufﬁciently such that that they have progressed to the stage of routine clinical use. It is
becoming apparent that the statistical methods used to evaluate the performance of new candidate
biomarkers are a major limitation in their development. Bayesian methods offer some advantages over
traditional statistical and machine learning methods. In particular they can incorporate external
information into current experiments so as to guide biomarker selection. Further, they can be more
robust to over-ﬁtting than other approaches, especially when the number of samples used for discovery is
relatively small.
In this review we provide an introduction to Bayesian inference and demonstrate some of the
advantages of using a Bayesian framework. We summarize how Bayesian methods have been used
previously in proteomics and other areas of bioinformatics. Finally, we describe some popular and
emerging Bayesian models from the statistical literature and provide a worked tutorial including code
snippets to show how these methods may be applied for the evaluation of proteomic biomarkers.
ã 2015 Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Advances in proteomic technology, in particular the widespread
use of liquid chromatography mass spectrometry (LC–MS), have
meant that vast amounts of information regarding protein and
peptide features can now be easily collected from bodily ﬂuids and
tissue, making them an ideal target to ﬁnd biomarkers of disease. A
mass spectrum sample can be represented as a series of peaks
where the mass to charge ratio (m/z) is depicted on the x-axis and
the molecule intensity on the y-axis. In statistical and bioinfor-
matic analysis each m/z ratio is treated as a separate variable where
its value is the intensity or abundance of the molecule at the given
m/z ratio. Each peak generally corresponds to a protein fragment or
peptide and so the objective of most biomarker discovery
experiments is to ﬁnd a subset of peptides that best discriminate
between the outcome groups [1]. It is widely accepted that use of
individual biomarkers are unlikely to sufﬁciently capture the
complexity and possible heterogeneity of a given disease [2–4]. For
this reason, most studies focus on ﬁnding a panel or signature of
differentially expressed protein or peptide features that are both
sensitive and speciﬁc enough to accurately predict a treatment or
disease state.
It has now become clear that the issue of ﬁnding a sensitive and
speciﬁc panel of biomarkers is much more complex than initially
anticipated. The area of proteomic biomarker discovery was
initially met with high hopes and great enthusiasm; however, this
fervor has weaned in recent years due to the inability of many
studies to validate candidate biomarkers that were initially
thought to be highly discriminatory [5,6]. Because of this, few
proteomic biomarkers have reached clinical utility despite much
government and industry investment [7,8]. Many articles have
reﬂected on the shortcomings of these earlier studies and have laid
out guidelines to rectify the oversights of initial experiments
[7,9,10].
Bayesian methods have been widely used in many areas of
bioinformatics and proteomics mainly due to the fact that they
lend themselves nicely to the challenge of analyzing complex,
noisy and often incomplete data [11]. Their growing popularity
over the last 20 years is mainly attributable to advances in
computational power which make ﬁtting Bayesian models much
more attainable for large datasets [12]. This article reviews the
literature on Bayesian methods in proteomics in general before
focusing on how Bayesian methods can be used for the statistical
analysis of mass spectra data for proteomic biomarker discovery
and evaluation. The beneﬁts of using Bayesian models compared to
other traditional and machine learning methods are discussed.
Reasons why Bayesian models might attain superior performance
in the validation of separate cohorts are also identiﬁed. Further-
more we highlight methods used in other areas of research as well
as other recent developments in Bayesian analysis which could
prove to be useful in future applications of proteomic biomarker
discovery experiments. Section 5.4 is a tutorial comprising a
worked proteomic validation example, using candidate biomark-
ers for the prediction of cardiovascular disease, in which two of
these Bayesian methods are tested and compared against each
other. This section also includes code samples which may be used
to run these models using freely available software. The tutorial
data set is also provided in order for the reader to test the code
provided and run the tutorial in their own time. Those not
interested in following the tutorial may wish to skip Section 5.4
and proceed directly to Section 6.2. What is Bayesian inference?
At the heart of all Bayesian methods is Bayes’ theorem,
p ujYð Þ / p uð Þ  pðYjuÞ
often expressed in words as:
posterior is proportional to prior times likelihood.
In the above equation Y is the experimental data and u are the
unknown parameters (e.g., peptide importance values). The
posterior distribution p ujYð Þis the joint probability distribution
of the unknown parameters given the observed data. Bayes’
theorem states that the posterior distribution can be calculated
from a combination of a probability distribution on the unknown
parameters of interest p uð Þ known as the prior distribution and a
conditional probability distribution p Yjuð Þof the data Y given the
parameters u, known as the likelihood.
Commonly, the prior distribution p uð Þ represents the knowl-
edge about the parameters of interest u before any data is collected.
Its shape represents the degree of certainty or knowledge about u;
for example a distribution with a sharp peak would express high
conﬁdence in our knowledge of u whereas a ﬂat or uninformative
prior would express no prior knowledge about the parameters of
interest. When data become available after an experiment has been
conducted, the information about the data and the parameters of
interest are combined through Bayes’ theorem to produce p ujYð Þ:
The main aim of any Bayesian analysis is to identify a credible set of
values that the parameters u can take given the observed data Y
[12,13], i.e., ﬁnd the posterior distribution.
Bayes’ formula is written with a proportionality constraint ð/Þ
because the full equation involves calculating a difﬁcult integral,
known as the normalizing constant. This problem is neatly
sidestepped by using ﬁtting methods such as Markov Chain Monte
Carlo (MCMC) which make inference about the posterior
distribution by sampling from it rather than computing it
explicitly.
3. Motivation for using Bayesian methods
One of the main advantages of Bayesian methods over non-
Bayesian statistical and machine learning techniques is the ability
to incorporate external information about the parameters through
the prior distribution. In proteomic experiments in particular a
great deal is already known about the parameters of interest before
an experiment takes place which can be incorporated into the prior
distribution. For example, if it was known that certain peptide
features tend to have high technical variability and be less
reproducible (as is often the case in MS analysis with low abundant
features whose intensity is near the limit of detection of the mass
spectrometer) a less informative prior could be used on these
peptides as opposed to the higher abundance, more reproducible
features.
One of the main reasons for the failure of many initial discovery
studies to validate according to [14] is the failure to accurately
model sources of experimental and biological variability. Many
traditional pre-existing techniques have been used to analyze the
data resulting from proteomic biomarker experiments such as
support vector machines, random forests, Lasso regression and
various other classiﬁcation methods [15–17]. However, the one
disadvantage common to all these methods is that they ignore the
uncertainty introduced to the data and assume that the
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however be modeled and incorporated into a Bayesian framework
in a consistent manner [18].
A common feature of proteomic discovery datasets is that the
number of variables tends to be much larger than the number of
samples, giving rise to problems of ‘over-ﬁtting’ when traditional
methods are used [19]. Over-ﬁtting means that the chosen model
ﬁts the current data set too precisely, giving over-optimistic
estimates of model performance that would not be repeated on an
external validation cohort. The model is thus apportioning signal to
random noise rather than identifying a true underlying model.
Traditionally over-ﬁtting is discouraged during the model building
phase by adding a penalty for the complexity of the model. This is
known as regularization. Bayesian models overcome over-ﬁtting in
a similar manner, though the penalty is more explicitly stated via
the prior distribution. Further ﬂexibility can be obtained by
marginalizing over (i.e., removing through integration) or shrink-
ing parameters [20,21] and so when used correctly will have a
better chance of validating on a separate cohort. For example,
Kuschner et al. used a Bayesian Belief Network (BN) on both
simulated and authentic proteomic data to discriminate between
patients with sub types of Human T-cell Leukemia Virus type 1, and
found that a BN with informative priors far outperformed
traditional linear and quadratic discriminant analysis with regards
to cross validated and test accuracy [22]. They also found that
biomarkers selected by the BN were far more stable over multiple
iterations than the other methods tested. Similarly, Vannucci et al.
[23] used probit models with Bayesian mixture priors and latent
variables to classify women with ovarian cancer from their mass
spectrum proﬁles and found that their method performed
accurately and selected biomarker panels which were consistent
with the literature.
4. Bayesian models currently used in proteomics
4.1. Biomarker discovery
The objective of many biomarker discovery experiments is
twofold; ﬁrst to accurately classify samples into groups and second
to select a subset of predictive peptide features or proteins which
can further be validated and measured using speciﬁc targeted
assays. Hence the analysis of biomarker discovery data is not only a
classiﬁcation prediction problem but could also be viewed as a
variable selection problem for high dimensional data where the
number of important parameters is small.
With respect to proteomic mass spectrometric biomarker
discovery, Bayesian models have not been as widely adopted as
in other areas of proteomics. Some examples of Bayesian feature
selection techniques have however emerged in the proteomics
literature [22,23]. Yu and Chen [24] use an ovarian cancer dataset
from the National Cancer Institute to showcase their proposed
version of a hierarchical Bayesian neural network. Essentially, this
deals with high dimensionality by ﬁltering variables through the
use of a Kolmogorov–Smirnov test that is used to set the hyper-
parameters on the prior distribution of a variable being selected to
a model. Deng et al. [25] also proposed an interesting application of
a Bayesian network where they used both microarray and mass
spec experiments to choose biomarkers of prostate cancer. In this
way their algorithm not only chose biomarkers which reported
high predictive accuracy but also those which were supported by
multiple sources of biological information. More recently the work
of Serang et al. used a Bayesian goodness of ﬁt approach to detect
the true number of differential features in an LC–MS experiment
[26]. This method has the advantage that is avoids the need to
specify many of the arbitrary cut-off choices common in most
proteomic analyzes such as the cut off for a “signiﬁcant” foldchange or a “signiﬁcant” q value. With respect to isobaric labelled
mass spectrometry data, Jow et al. proposed a hierarchical
Bayesian method which was found to perform well in a variety
of simulated and real proteomic experiments [27]. This Bayesian
methodology in particular has the advantage that it can easily
integrate multiple data experiments into a single model. Koh et al.
proposed an alternative model based approach for analyzing data
resulting from label based proteomic experiments [28]. They note
that with labeling approaches many of the ratios used to identify
differentially expressed proteins ignore the fact that some proteins
are quantiﬁed using more peptides and are therefore more
reproducible than others. Their proposed method incorporates
this knowledge regarding the reproducibility of the protein
quantities and models the hierarchical relationship between
peptides and proteins directly giving greater importance to
proteins which are the most reproducible.
4.2. Other areas of proteomics
Bayesian methods have inﬁltrated many other areas of
proteomic research apart from biomarker discovery. At a
functional and structural level there are many examples of early
adoptions to a probabilistic framework in areas such as sequence
alignment [29,30] and predicting protein structures [31–33].
Bayesian methods have also proven popular for ﬁnding protein
functions as well as predicting protein–protein interactions
[34,35].
Mass spectrometry, and in particular peptide and protein
identiﬁcation from mass spectrum fragmentation data has also
seen many contributions from Bayesian models. Serang et al. [36]
proposed a Bayesian framework for protein inference with
degenerate peptides to calculate the posterior probability of a
given peptide belonging to a protein, which was found to
outperform the popular software ProteinProphet on a number of
datasets. Li et al. [37] also proposed a fully probabilistic approach to
protein identiﬁcation, however, their method was found to be too
computationally intensive for use on large datasets [36]. Protein-
Prophet itself uses an empirical Bayes approach in which the prior
is estimated from the data. Their method uses a two component
mixture model to understand the distribution of peptide search
scores observed for all designated peptides [38,39]. Another
software ProFound identiﬁes proteins by searching through
existing sequence databases and uses Bayes’ theorem to calculate
the posterior probability that each protein in the database is the
current sample protein being analyzed, given the experimental data
and other available background information. Proteins are then
ranked according to their posterior probability [40].
5. Possible Bayesian applications for biomarker discovery
The use of Bayesian methods for the statistical analysis of
proteomic mass spec discovery data is still quite a new and
emerging area and to-date has not reached the maturity of other
areas of bioinformatics and systems biology. As mentioned
previously, mass spectrometry discovery data tends to have far
more variables ðpÞ than samples ðnÞ (commonly referred to as small
n large p) however it is expected that very few of the variables
measured are truly related to the response or outcome. For this
reason many studies have focused on ﬁnding a small biomarker
panel which can accurately predict disease [5,41]. There is a vast
literature on Bayesian models used for feature selection on small n
large p datasets in other areas of research, which thus could be
applied to proteomic biomarker discovery. This section will outline
some existing Bayesian models from the statistical literature which
could have interesting applications to the area of proteomic
biomarker discovery.
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The Lasso model for linear regression is one of the most widely
used methods for variable selection in high dimensional data [42].
The Lasso has also proven popular in various areas of proteomics.
Huang et al. [43] proposed ProteinLasso which uses the Lasso for
protein inference; Friedman et al. also showcased the graphical
Lasso to ﬁnd protein networks in ﬂow cytometry cell signaling data
[44]. For other examples see [45,46]. As previously stated,
regularization is a popular form of variable selection where a
penalty is applied to the parameters in order to discourage
complex models where many variables are chosen. The Lasso is a
regularized version of ordinary least squares regression (for a
continuous response) which balances model ﬁt and model
complexity by adding a penalty parameter which controls the
absolute sum of the regression coefﬁcients included in the model.
The higher the penalty the more coefﬁcients will have a value of
zero and will be effectively eliminated from the model.
It was noticed that the coefﬁcients returned by the original
Lasso correspond to the mode of the posterior distribution in a
Bayesian setting when a Laplace (double exponential) prior is
placed on the parameter vector pðbjs2Þ where s2 refers to the
model variance; which led to the inception of the Bayesian Lasso
[47]. The Bayesian Lasso allows for the full posterior of the model
coefﬁcients to be explored rather than just a point estimate, and so
can give more instructive information regarding variable selection.
Also, tuning parameters that control how harsh a penalty is placed
on the model coefﬁcients can be treated as unknown random
variables and so their posterior distribution can also be sampled.
This avoids the need for ad-hoc choices of tuning parameters such
as those used in the traditional Lasso model. The Bayesian Lasso
has been used in various biomedical and bioinformatics studies in
recent years and has proven a popular approach for variable
selection in data which have a sparse parameter space [48–50].
There is a freely available R package to run the Bayesian Lasso
called “reglogit” [51] which is showcased in Section 5.4. The
Bayesian Lasso can also be run using a package called rJAGS [52]
which is shown in Section 5.4.
5.2. Other Priors for Variable Selection
There is a wide array of literature proposing different shrinkage
priors other than that of the Laplace prior (used by the BayesianFig. 1. Example of a binary clLasso above) which have been shown to be optimal in various
settings. For example, Dunson and Lee suggest use of a generalized
double Pareto prior [53] and Grifﬁn and Brown suggest a normal-
gamma prior on b, which is a generalization of the double
exponential prior [54]. One of the most popular rivals to the
Laplace prior of the Bayesian Lasso is the Horseshoe prior [55].
Carvalho et al. claim that the main advantages to the use of the
horseshoe prior is that it is robust to large signals and is very
effective in shrinking noise variables [55]. The horseshoe
distribution is very heavy tailed with an inﬁnitely large spike at
zero. This means that coefﬁcients near zero can be shrunk very
efﬁciently but also that coefﬁcients far from zero will not be shrunk
as severely, allowing for large signal if it is evident in the data. The
horseshoe prior, Bayesian Lasso and ridge regression can be run
using package “monomvn” in R [56].
A less severe shrinkage prior, though still widely used for
Bayesian variable selection, is Zellner’s g prior, where the prior on
the parameter vector takes the form: b  N b0; gs2 XTX
 1 
.
Here, b0 is the value around which the regression coefﬁcients are
thought to center (usually taken to be 0); the prior on s2 is
generally a non-informative prior and g is the hyper-parameter on
the model coefﬁcients controlling the degree of shrinkage [57].
This is a popular prior because of its computational simplicity for
calculating marginal likelihoods (the likelihood function where
some parameters have been removed through integration), and the
fact that only g has to be estimated. There have been many
suggestions on how to treat g. Some authors suggest placing a prior
distribution whereas others suggest using ﬁxed values or
estimating the value for g using Empirical Bayes methods; see
[58,59] for more information. Use of the g prior with a probit model
has previously been proposed in the context of gene microarray
studies to classify a number of diseases including colon cancer and
leukemia [60] and also in gene selection for expression data [61], as
well as in a ridge regression for high dimensional microarray breast
cancer data [59]. Regression using the g prior can be run in R using
the BMS package [62].
An alternative to shrinkage is to directly model the probability
of inclusion of a variable. A popular version of this for regression
problems is that of Kuo and Mallick [63]. They introduce a vector of
indicator variables which signify inclusion or exclusion of eachassiﬁcation decision tree
58 B. Hernández et al. / EuPA Open Proteomics 9 (2015) 54–64parameter in the model as shown below [63].




Here yi is the value of response variable y for observation i,bj is the
coefﬁcient for variable j, Ij is the indicator term which is 1 if
variable j is to be included in the model and 0 otherwise,xij is the
value of explanatory variable j for observation i and ei is random
noise associated with observation i. Usually independent priors are
placed on the b vector and the indicator vector I. One of the
advantages of this method is that it doesn’t require much tuning.
However, it can be slow to ﬁt [64].
5.3. Bayesian non-parametric models
Both the Bayesian Lasso and other shrinkage priors used for
regression models assume that the variables are linearly related
and that variable interactions are known in the model speciﬁca-
tion. In this section we discuss examples of non-parametric
Bayesian models which could be applied to proteomic biomarker
discovery.
5.3.1. Bayesian CART
Classiﬁcation and regression decision trees (CART) are a popular
method used in many areas of proteomics and in particular
biomarker discovery and evaluation [65–67] largely due to the fact
they do not assume the covariates are linearly related to the
response, often an unreasonably strong assumption in complex
biological data. A key aspect of decision trees is that, unlike other
regression models, they automatically select and include impor-
tant variable interactions as part of the model building process and
do not require these interactions to be explicitly speciﬁed in the
model building. Decision trees consist of internal nodes where
questions are asked based on a split rule consisting of a variable
and a threshold, and terminal nodes which separate the
observations into distinct groups. Observations which satisfy the
split rule at each internal node are sent to the left hand daughter
node and those which do not are sent to the right hand daughter
node. Observations are iteratively split into left and right hand
daughter nodes as they pass through each internal node in turn
until a terminal node is reached. Fig. 1 shows an example of a
simple decision tree for a binary classiﬁcation problem. Using Fig. 1
as an example model to predict between two groups (control and
treatment) it can be seen that all patients with actin levels
5.3 would be predicted as belonging to the control group; all
patients with actin levels >5.3 and keratin levels 10.2 would be
predicted as treatment and all patients with actin levels >5.3 and
keratin levels >10.2 would be predicted as control. As can be seen,
decision trees are easily interpretable, naturally perform variable
selection, allow for complex non-linear interactions and also
perform prediction, which are the main reasons for their
popularity in biomarker evaluation studies [65–67].
The Bayesian version of CART (Bayesian CART) has not, to our
knowledge, yet been used in proteomic biomarker discovery and
evaluation but could have very interesting applications in this area
as they combine the advantages of Bayesian models with those of
traditional decision trees discussed above. For a Bayesian CART
model, the data in each terminal node of the tree is assumed to
follow a multinomial distribution for classiﬁcation problems. This
allows the probability of belonging to a given class to be computed
which can provide richer information than merely knowing the
predicted labels.
Chipman et al. proposed a version of Bayesian CART which
samples from the posterior distribution of the trees using MCMC[68]. This essentially means that many trees are sampled from the
posterior distribution by creating a chain of k trees T0; T1 . . . Tk. At
each iteration k, a new tree is proposed and either accepted or
rejected according to how well it matches the observed data and
the prior distribution. The new trees are proposed by either growing
or pruning (making the most recently accepted tree bigger or
smaller) or changing or swapping internal nodes of the most
recently accepted tree. This algorithm continues iteratively sam-
pling trees until the model parameter estimates become stable. At
this stage it is usuallyassumed that the algorithm has converged and
we have samples from the posterior distribution of trees.
The tree size and shape is determined by a prior probability of a
terminal node splitting Psplit ¼ a 1 þ dið Þb where d refers to the
depth of the current terminal node iand a and b are penalties on
the tree size and shape respectively. As discussed, trees are
sampled by growing, pruning, changing or swapping the current
tree in the algorithm. Grow and prune moves are synonymous with
node birth and death where a random terminal node is either
converted into an internal node by further splitting it into two
daughter nodes (grow) or a random internal node with two
terminal daughter nodes is collapsed into a terminal node (prune).
Growing or pruning a tree alters the size of the tree. Tree structure
is altered by changing or swapping nodes where a new split rule is
chosen for a given internal node in a tree or an internal parent–
daughter pair of nodes is swapped around respectively.
5.3.2. Other Bayesian tree models
There have been many other variations on the Bayesian CART
model of [68]. One application which was developed independently
and at the same time is [69]. The Bayesian CART model of [69] differs
from [68] in that their tree prior only requires one parameter
determining the number of terminal nodes in the tree and does not
include further parameters determining the tree shape and size.
Theyalso use a similar MCMC approach to sample from the posterior
distribution of tree models [68]. More recently [70] proposed an
alternative prior on the tree p Tð Þ as shown below:
p Tð Þ ¼ a m0 Tð Þð Þ
Y
u 2a Tð Þ
bðml uð Þ Tð Þjmu Tð ÞÞ
Here m0 Tð Þ refers to the number of terminal nodes in tree T,a and b
determine the tree size and shape respectively,mu refers to the
number of terminal nodes in the sub-tree below node u and ml uð Þ is
the number of terminal left daughter nodes in the sub-tree below
node u. In addition to the four proposal steps of [68] and [69]
described above, [70] suggest an additional proposal move to
sample new trees called the “restructure proposal”, this move
searches for alternative trees that would result in the same
terminal nodes as the current accepted tree. They claim that this
overcomes the problem of slow mixing found in previous Bayesian
CART models, as radically different trees can be proposed rather
than just local changes of previously accepted trees.
5.3.3. Bayesian additive regression trees (BART)
Bayesian additive regression trees (BART) [71] is a fundamental
extension of Bayesian CART and is a non-parametric tree-based
ensemble method which brings with it all the advantages of a fully
probabilistic model. The BART model uses a sum of multiple
Bayesian CART trees as proposed in [68] in its formulation.
Posterior predictions are then constructed by adding the MCMC
samples over all trees. Point and credible intervals for each
predicted data point can also be obtained by taking the appropriate
quantiles from the distribution of the MCMC samples for each
predicted value of the response variable.
The idea of CART ensemble methods is not new, in fact the most
widely used of these methods, the random forest, was invented in
B. Hernández et al. / EuPA Open Proteomics 9 (2015) 54–64 592001 [72] and has been a popular method in the area of proteomic
biomarker discovery [41,73,74]. BART, to the authors’ knowledge,
has not yet been applied to a proteomic setting, however a
multiclass version has been used to classify satellite images [75]
and a very recent application to gene regulation data using
informative priors for biomarker selection has also been imple-
mented [76]. Another extension of the BART method has also been
proposed for use on high dimensional survival data and was
successfully showcased on a number of gene expression datasets
[77].
The recent addition of a more efﬁcient parallelized software
package in R called bartMachine [78] means that this method can
now be easily implemented for high dimensional datasets such as
those commonly found in MRM and smaller proteomic biomarker
discovery experiments. Due to memory constraints and computa-
tional complexity of the model however, some preprocessing of the
data may be needed for very high dimensional data. Code snippets
to implement BART in R have been included in Section 5.4.
Bayesian CART and BART models offer many advantages over
traditional tree and tree-ensemble methods for biomarker
discovery. Their main beneﬁt is the fact that credible intervals
can be constructed around the point estimate of the probability of
belonging to a given class. This could have large implications for
the quality of clinical decisions made based on the output of such
methods. Hence, Bayesian tree models provide the user with a
much richer output on which to make decisions compared to
traditional CART models.
A summary of the main advantages of the Bayesian Lasso,
Bayesian decision tree methods and BART discussed in this section
can be seen in Table 1.
5.4. Worked example: implementation of Bayesian inference for
biomarker evaluation in R
This section provides a worked example using the Bayesian
Lasso and Bayesian additive regression trees (BART) models
(described in the previous section) using freely available software
in the statistical programming language R. Here we use an
illustrative example of LC–MS data which was collected for
498 patients, 150 of which had a cardiovascular disease and 348 of1. se t.s eed (100)
2. #s et num ber of ite rat ions
3. T = 1000
4. re g_l ogi t_mod el = reg logit (T, trai ning_ respo nse,tra ini ng_ data, norm ali ze=FA LSE)whom were healthy. A total of 36 proteins were measured by a
targeted approach (MRM) in each patient sample. The objective ofTable 1
Comparison of Bayesian Lasso model with Bayesian decision tree based models.
Bayesia
Will work for small n large p data U 
Automatically includes high order variable interactions 
Effectively eliminates non-predictive variables U 
Provides a variable importance score 
Finds linear relationships U
Finds non-linear relationships 
1. re g_l ogi t_pre ds = pre dict(reg_l ogi t_mod el,this study was two-fold as with many biomarker discovery
experiments:
1. To build a classiﬁer which can accurately predict between the
two groups and,
2. To ﬁnd a subset of proteins/peptide features which are
important in discriminating between the groups.
The dataset described is provided in the supplementary
material where all identifying information has been removed.
Therefore peptide features in the following tutorial will be referred
to using their column number in the dataset provided rather than
their sequence. This data set is shown for illustrative purposes
only, however the analyses and code used here are equivalent for
higher dimensional datasets where p >> n as is common in shotgun
discovery experiments. To compare fairly across all analyses the
data set was split into a training and test set where a random
sample of 398 patients were chosen to build the model and the
remaining 100 were used to test the model. This ensures that none
of the models over-ﬁt to random artifacts in the data. In the
following code snippets the response variable for the training data
will be referred to as “training_response” and the response variable
for the test data as will be referred to as “test_response”. Similarly,
the explanatory variables for the 398 training observations will be
referred to “training_data” and the explanatory variables for the
100 test observations will be referred to as “test_data”.
It should be noted that with shotgun proteomic experiments
where the number of peptides measured can reach tens of
thousands much consideration should be given to the appropriate
sample size to use. Although sample size calculation is beyond the
scope of this article the interested reader may wish to refer to
previous work where we show how varying sample sizes can
affect the overall classiﬁcation performance of a model [79].
5.4.1. Package reglogit
An MCMC implementation of the Bayesian Lasso which is
equivalent to a logistic regression with double exponential priors
can be run using the R package reglogit [51,80]. The Bayesian Lasso
model is run by default as follows:Simple prediction of the class of each sample can also be






1. li bra ry( ROCR)
2. pr edi cti on=pr edict ion (reg_ logit _pr eds$m p,tes t_respo nse )
3. pe rfo rma nce=p erfor man ce(pr edict ion ,"auc ")
4. re g_l ogi t_auc =perf orm ance@ y.val ues [[1]] [1]
60 B. Hernández et al. / EuPA Open Proteomics 9 (2015) 54–64and the classiﬁcation rate can be calculated using the following
code:Fig. 2. ROC curve comparison of Lasso using package reglogit and rJags and BART
using package bartMachine
1. cl ass _ra te=su m(reg _lo git_p reds$ c == tes t_res ponse)Analysis of the output for the cardiovascular disease data
showed that the Bayesian Lasso model performed quite well in this
instance and identiﬁed 74% of the test samples correctly with an
area under the ROC curve of 0.65 (see Fig. 2).
Important variables can be chosen by looking at the posterior
distribution of the variable parameters. The 2.5%, 50% and 97.5%
quantiles of the posterior distribution of the variable parameters
can be viewed using the following code:
1. bu rni n = (1:( T/10) )
2. qu ant s = t(ap ply(reg_ logit _mode l$b eta[-
burni n,] ,2,fu nctio n(x )quan tile( x,p robs= c(0.2 5,0.5,0 .97 5)) ))
Choosing the variables whose 95% credible intervals did not
include zero, we found that the peptides 3, 12 and 13 were given
non-zero coefﬁcients and hence were important in distinguishing
between those patients who had experienced cardiovascular
disease or not.
5.4.2. JAGS
The Bayesian Lasso can also be run using a package called rjags
[52] which requires installation of the JAGS software. The use of
rjags does require some programming skills as all models are
written by the user. However this allows the user full access to all
information regarding the model and the ability to easily change
priors and other model assumptions. An example of how a
Bayesian Lasso might be run in JAGS is included in the following
code:
Here non-informative priors have been set on the beta and
lambda parameters, however these could be easily changed if1. re qui re( rjags )
2. da ta= lis t(y=r espon se, X=dat a,n=n row (data ),p
3. #i nit ial ise parame ter valu es
4. in it= lis t(lam bda=1 ,al pha=0 ,beta =re p(0,p ))
5. mo del str ing="
6. mod el {
7. for (i in 1:n) {
8. #w rite a log ist ic re gress ion
9. lo git(t heta[ i]) <-alp ha+in pro d(X[i ,],
10. y[ i]~db ern(t het a[i])
11. }
12. for (j in 1:p) {
13. #s et a doubl e expone ntial pr ior on t
equiv ale nt to plac ing a do uble exp onent ial
14. be ta[j] ~ddex p(0 ,lamb da)
15. }
16. #set a va gue prio r on the inte rcept te
ce so th is is equi val ent to alp ha~ N(0,1 00)
17. alph a~dno rm(0, 0.0 1)
18. #set a we akly inf ormat ive prio r on hyp
19. lamb da~dg amma( 0.1 ,0.1)
20. }
21. "previous experiments or expert opinion deemed some peptides to
be better candidate biomarkers than others. The data used in thismodel includes all 498 samples where the response variable for the
test samples has been set to NA. rjags will automatically give
predicted values for all samples whose response is ﬂagged as NA.=n col(dat a))
be ta)
he beta para met ers (The Baye sian LASSO is
 prior on be ta)
rm . JAGS use s precis ion inst ead of var ian
er-parame ter la mbda
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be viewed using the following code:
This Lasso model shown here was run using MCMC. In the
snippet above we can see that 1000 samples were taken from the
posterior distribution of our model parameters. An important1. #u se the coda .samp les comm and to view parame ter out put an d dia gnost ics
2. Outpu t=coda.s ample s(m odel= model ,va riabl e.nam es=c("a lph a","beta ","la mbd a"),n .iter =10
00,th in= 10)aspect of MCMC is to check that the samples taken have reached
what is known as convergence, i.e., that the MCMC chain has
reached its stationary or desired posterior distribution. Conver-
gence of the model parameters can be checked as follows:
1. #c hec k conver gence
2. ge lma n.d iag(o utput )
3. ge lma n.p lot(o utput )
The 95% credible interval for the parameter estimates can also
be viewed as follows:
1. #g et qua ntile s of the mode l par ame ters
2. qu ant ile s=sum mary( win dow(o utput ,bu rnin= 2000) )[[2]]
Choosing those variable parameters whose 2.5% and 97.5%
quantiles do not include 0 found that variables 3, 12 and 27 had
non-zero coefﬁcients according to this model, which corresponds
to peptides numbered 3,12 and 27 as being important predictors of
cardiovascular disease. In this case the JAGS model predicted 67%
of the test cases correctly and gave an area under the ROC curve of
0.66 (see Fig. 2).
As mentioned earlier, the posterior distribution of the model
parameters can be explored in a Bayesian setting. This means
that credible intervals for the probability of having a cardiovas-
cular event can be constructed with these models rather than
just having access to a point prediction. The quantiles of
the predicted probabilities for each of the test samples can be1. op tio ns( java. param ete rs = "-Xmx 500 0m")
2. li bra ry( bartM achin e)
3. se t.s eed (100)
4. bm =ba rtM achin e(dat a.f rame( train ing _data ),tra ining_r esp ons e,num _tree s=5 0,num _iter ati
ons_a fte r_bur n_in = 1000,m em_ca che _for_speed = FALS E,s eri alize = TR UE)viewed as follows:1. #s ee qua ntile s for th eta
2. ou tpu t_t heta= coda. sam ples( model =mo del,v ariab le.name s=c ("t heta"),
3. n.iter =1000 ,th in=10 )
4. #p lot 95 % CI for the proba bilit y of hav ing cardiova scu lar  dise ase
5. th eta _qu ants= summa ry( outpu t_the ta[ ,test _samp les])[[ 2]]To illustrate the usefulness of this additional information we
shall take two patients numbered 60 and 367. Patient 60 has a
median predicted probability of 25.61% of having cardiovasculardisease and patient 367 has a median predicted probability of
4.25%. In the absence of further information (as with machine
learning methods) the clinicianwould give both patients the all clear.
However, if we look at the 2.5% and 97.5% quantiles for patient 60 we
see they range between 7.46% and 62.79%, respectively whereasthose for patient 367 range from 1.01% to 13.29%. This additional
information means that the model is very sure that patient 367 does
not have cardiovascular disease; however it is not at all sure as to the
class of patient 60. If a clinician was merely basing the prognosis on
the median estimate, they would most likely quite conﬁdently
diagnose both patients as healthy. However knowing that the
estimate for patient 60 could vary anywhere between 7.46% and
62.79% might change their opinion and hence the medical advice
offered to this patient. For example patient 60 may be sent for further
diagnostic tests. Alternatively, knowing the 95% credible interval for
patient 367 ranges from 1.01% to 13.29%, might give the clinician
added conﬁdence as to the true diagnosis of this patient. In reality
patient 60 did have cardiovascular disease and patient 367 was
healthy, so basing predictions on a point estimate would have led to
the misdiagnosis of patient 60 in this case. Bayesian decision theory
[81], not discussed here, provides a more nuanced approach to
making such decisions.
5.4.3. bartMachine
BART can be run using the package bartMachine in R [82]. The
bartMachine function creates a Java virtual machine which
requires the user to set the amount of memory to be used by
the function. This can be set using the options() command in R as
shown in the following code. Here we have set 5Gb of RAM as the
limit for the virtual machine. The serialize=TRUE command allows
the BART model to be saved and loaded at a later date otherwise all
information regarding the model will be lost once R is closed. The
bartMachine model can be run on the training data as follows:Once the model is run on the training data using the code above,
predictions and the full posterior of the test samples can be viewed
as follows:
1. #g et pre dicte d val ues for test sam ples
2. pr eds =ba rt_pr edict _fo r_tes t_dat a(b m,dat a.fra me(scal e(c vd_ data[ test_ sam ps,]) ),res pon
se[te st_ samps ])
3. #l ook at the poste rio r sam ples for test data
4. te st_ sam ps_po steri or=bart_ machi ne_ get_p oster ior(bm, dat a.f rame( scale (cv d_dat a[tes t_s
amps, ])) )
5. #g et the 2.5% ,50% and 97,5 % qua nti les of the poster ior te st sa mples
6. po ste rio r_qua ntile s=t(appl y(tes t_s amps_ poste rior[[3 ]], 1,f uncti on(x) qua ntile (x,pr obs
=c(0. 025 ,0.5, 0.975 ))) )
62 B. Hernández et al. / EuPA Open Proteomics 9 (2015) 54–64In this case BART marginally outperformed both implementa-
tions of the Lasso for this data in terms of the classiﬁcation rate of
71% for the test samples. Fig. 2 shows the ROC curve for all three
methods compared in this section. As can be seen BART also
outperformed both implementations of the Lasso in terms of the
area under the ROC curve giving an AUC of 0.68. bartMachine
unlike the Lasso does not eliminate variables from the model and
as such all variables are given an importance score which is based
on the number of times each variable was selected for each tree in
the model. The importance score for each variable can be seen by
using the following command:1. #g et var iable impo rta nce scores
2. ge t_v ar_ props _over _ch ain(b m)In this case the bartMachine model found that variables 13, 2,
14, 3, 34, 23 and 12 were given the highest importance. It is
interesting to note that all but one of the variables identiﬁed by
both Lasso implementations were also identiﬁed as the most
important according to BART. A vignette for the bartMachine
package can be found at [78].
6. Discussion
We have identiﬁed a number of potential areas from the
Bayesian statistical literature which could be applied to proteomic
discovery data. We have also guided the reader in the use of these
models by supplying tutorial style example code and have
illustrated these methods using an authentic proteomic data set
that was obtained for the purpose of developing biomarkers to
predict cardiovascular disease.
Bayesian modeling for proteomic biomarker discovery and
evaluation data is a relatively new and emerging ﬁeld with exciting
future opportunities. Many articles have discussed the possible
reasons why candidate biomarkers reported in numerous bio-
marker discovery experiments have subsequently failed to be
validated. Some of the issues cited in the literature may be
alleviated by the incorporation of a probabilistic model. It has been
suggested that a major reason for this lack of success is that the
original models used to discover potential markers over-ﬁt the
data. This is due to the fact that biomarker discovery datasets
(especially those emerging from mass spectrometry) tend to be
small n large p. Notably, Bayesian models provide a potential
solution as when used with sensible priors they tend to be more
robust to over-ﬁtting than non-Bayesian models as the full
posterior distribution of the model parameters is given. Another
possible reason for the failure of many biomarkers to validate is the
general lack of incorporation of technical and scientiﬁc knowledge
about the validation process into the statistical models used to
analyze biomaker validation data. With careful modeling Bayesian
methods can easily include this information including for exampleknowledge of the variability introduced to the data through the
various sample processing and experimental stages before data are
subjected to statistical analysis.
The area of Bayesian variable selection for high dimensional
data is a new and rapidly developing ﬁeld. Decision tree models
and ensemble methods in particular have traditionally been very
popular for biomarker discovery as they are easily interpreted, are
non parametric and automatically include important interactions
without prior speciﬁcation by the user. We believe the many recent
advances in Bayesian tree and ensemble methods have very
interesting application in the arena of proteomic biomarkerdevelopment by improving the selection and evaluation of
candidate biomarker panels.
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